British Columbia Cancer Agency Agrees to Fund Genomic Health's Oncotype DX | GenomeWeb

NEW YORK (GenomeWeb) ─ The British Columbia Cancer Agency has agreed to reimburse for Genomic Health's Oncotype DX breast cancer recurrence test.

The multi-gene expression diagnostic is available in four other Canadian provinces in addition to British Columbia, including Ontario, Quebec, Saskatchewan, and Newfoundland.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.